Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person Inactivation of over-expressed wild type EGFR by Cetuximab recombinant antibody

Class:Id	Reaction:1248677
_displayName	Inactivation of over-expressed wild type EGFR by Cetuximab recombinant antibody
_doRelease	TRUE
_timestamp	2016-08-15 16:43:46
authored	[InstanceEdit:1972359] Orlic-Milacic, M, 2011-11-04
compartment	[Compartment:984] extracellular region [Compartment:876] plasma membrane
created	[InstanceEdit:1248676] Orlic-Milacic, Marija, 2011-04-12
disease	[Disease:1248679] head and neck squamous cell carcinoma [Disease:1248674] large intestine cancer [Disease:1500689] cancer
edited	[InstanceEdit:1972360] D'Eustachio, P, 2011-11-07 [InstanceEdit:1972361] Matthews, L, 2011-11-07 [InstanceEdit:1990853] Wu, G, 2011-11-07
input	[EntityWithAccessionedSequence:179837] EGFR [plasma membrane] [Homo sapiens] [ProteinDrug:1248673] Cetuximab [extracellular region]
isChimeric	FALSE
literatureReference	[LiteratureReference:1660566] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [LiteratureReference:1660577] Structural basis for inhibition of the epidermal growth factor receptor by cetuximab [LiteratureReference:1660568] Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study
modified	[InstanceEdit:1248680] Orlic-Milacic, Marija, 2011-04-12 [InstanceEdit:1248681] Orlic-Milacic, Marija, 2011-04-12 [InstanceEdit:1643698] Orlic-Milacic, Marija, 2011-10-11 [InstanceEdit:1660589] Orlic-Milacic, Marija, 2011-10-13 [InstanceEdit:1667623] Orlic-Milacic, Marija, 2011-10-14 [InstanceEdit:1667628] Orlic-Milacic, Marija, 2011-10-14 [InstanceEdit:1979631] Orlic-Milacic, Marija, 2011-11-08 [InstanceEdit:1990842] Orlic-Milacic, Marija, 2011-11-14 [InstanceEdit:1990860] Orlic-Milacic, Marija, 2011-11-14 [InstanceEdit:1998737] Orlic-Milacic, Marija, 2011-11-19 [InstanceEdit:2023591] Matthews, L, 2011-12-09 [InstanceEdit:8935887] Orlic-Milacic, Marija, 2016-08-15 [InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
name	Inactivation of over-expressed wild type EGFR by Cetuximab recombinant antibody
output	[Complex:1248675] EGFR:Cetuximab [plasma membrane] [Homo sapiens]
releaseDate	2011-12-06
reviewed	[InstanceEdit:1990843] Greulich, H, 2011-11-15 [InstanceEdit:1990844] Savas, S, 2011-11-15
reviewStatus	[ReviewStatus:9821382] five stars
species	[Species:48887] Homo sapiens
stableIdentifier	[StableIdentifier:2016307] R-HSA-1248677.3
summation	[Summation:1248678] Cetuximab binds to the extracellular domain of EGFR and bloc...
(hasEvent)	[Pathway:5638303] Inhibition of Signaling by Overexpressed EGFR [Homo sapiens]
[Change default viewing format]

No pathways have been reviewed or authored by Inactivation of over-expressed wild type EGFR by Cetuximab recombinant antibody (1248677)